A Multicenter, Randomized, Double-Blinded, Monotherapy-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of the Acarbose and Metformin in Loose-Dose Combination Compared to Metformin Monotherapy in Subjects WithType 2 Diabetic Mellitus (T2DM) That is Inadequately Controlled by Metformin Monotherapy
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Acarbose/metformin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Bayer
- 21 Sep 2018 Planned End Date changed from 17 Jun 2019 to 11 Sep 2019.
- 21 Sep 2018 Planned primary completion date changed from 17 Jun 2019 to 11 Sep 2019.
- 31 Aug 2018 Biomarkers information updated